Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dyadic Welcomes New Chief Operating Officer

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer.

Dyadic International, Inc. has announced that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June.

Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm’s Investment Bank.

“Danai has significant financial and operational experience in the renewable energy and bio-based chemical space, and will be a tremendous asset to Dyadic,” said Mark Emalfarb, Dyadic’s President and Chief Executive Officer.

Emalfarb continued, “As EVP and COO, Danai will play a key role in driving our business development and licensing efforts, as well as corporate strategic planning and operational improvements across the globe.”

“As a long-time advisor to Dyadic, I am intimately familiar with the Company and thrilled to have the opportunity to join the team” said Brooks.

Brooks continued, “Dyadic continues to compete with larger industrial enzyme companies using its game-changing C1 enzyme expression platform. Together, we will continue to build commercial momentum through enzyme sales and strategic partnerships across a wide range of sectors including cellulosic biofuels, biopharmaceuticals and industrial applications. We look forward to introducing new C1-based products to the many industries and companies that can benefit from C1’s ability to produce enzymes and other proteins with class leading performance.”

While at J.P. Morgan, Brooks advised clients across a broad spectrum of sectors, including chemicals, renewable energy and industrials.

He has held senior operational, engineering and manufacturing positions with Dell Inc., Mars Inc. and Ford Motor Company.

He received a B.S. in Industrial Engineering and Master of Engineering from Cornell University, a Master of Engineering Management from Northwestern University and an MBA from Northwestern’s Kellogg School of Management.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NEW U.S. Patent Issued to Dyadic International
The Patent is entitled “Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose”.
Tuesday, March 25, 2014
Dyadic Issued New U.S. Patent
Dyadic International has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office.
Monday, November 11, 2013
BASF and Dyadic Enter Into Research Agreement
Dyadic’s C1 technology platform enables BASF to develop enzymes for multiple market segments.
Thursday, May 16, 2013
Sixth U.S. Patent Issued to Dyadic International
U.S. Patent No. 7,794,962 - “High Throughput Screening of Expressed DNA Libraries in Filamentous Fungi”.
Thursday, October 14, 2010
Dyadic Granted Patent for High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi
Expands patent protection for Dyadic's C1 host technology platform for applications in cellulosic ethanol and other key markets.
Friday, October 20, 2006
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!